Precision BioSciences Receives Fast Track Designation from U.S. Food and Drug Administration for PBCAR269A, an Investigational Allogeneic CAR T Therapy for Relapsed/Refractory Multiple Myeloma

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs